Carien Creutzberg

Carien Creutzberg is the principal investigator of the landmark PORTEC randomized trial series (PORTEC-1, -2, and -3) that defined the role of adjuvant radiotherapy and chemoradiotherapy in endometrial cancer. PORTEC-1 established that intermediate-risk endometrial cancer could be treated with vaginal brachytherapy alone, sparing many patients pelvic radiation toxicity. PORTEC-3 integrated concurrent chemotherapy with radiation for high-risk patients and demonstrated improvement in recurrence-free survival. Her integration of molecular markers into the PORTEC studies directly shaped molecular risk classification of endometrial cancer.